OBJECTIVES: Pneumococcal disease is a public health concern worldwide. This study evaluates the budget impact of PCV 13 vaccination with free campaign for corporations, versus no vaccination for individuals with 60+ years of age. METHODS: A budget impact analysis was developed considering vaccination costs, wage and productivity loss from employee absence due to sickness or death. Clinical events were calculated using a Markov model with individual-level simulation considering a cohort of 1.000.000 individuals of 60 years of age in a time horizon of 5 years, assuming a retirement age of 65. Vaccines effectiveness’ were extrapolated from infant results. Absence days due to health events were retrieved from national labor legislations.  Average wage was retrieved from the Brazilian Institute for Geography and Statistics (IBGE) 2012 data and productivity was estimated from the indicator ‘revenue generated by the employee’, from a market research developed by Exame magazine in 2012 using IBGE and the Brazilian Central Bank data. The base case considered a large corporation in Brazil with approximately 4.000 eligible individuals. Values were expressed in 2012 US$. RESULTS: PCV13 with free campaign totaled US$61,40 per employee. Productivity loss due to sick leave and death per employee was respectively US$641,97 and US$712,61 for PCV13 and no vaccination. Considering all evaluated costs per employee and the number of eligible individuals, PCV13 and no vaccination totaled US$2.813.483,66 and US$2.850.451,98 respectively, representing US$36.968,32 of total savings for PCV13 vaccination when compared to no vaccination. CONCLUSIONS: The PCV13 vaccination plus a free campaign initiative is estimated to save costs to the employee, when compared to no vaccination, mainly driven by productivity loss due to sick leave and death, which represented 115,52% of the total investment in a time horizon of 5 years for individuals of 60+ years of age.